Daratumumab,Talquetamab,Teclistamab,Pomalidomide
janssen,genmab
['cart,(-cartitude)', 'daratumumab', 'teclistamab']
teclistamab sc combined with daratumumab sc, weekly/q2 weekly dosing schedules, shows a response rate 78%, mrd- 27% at 10-5 via ngs, crs ~61% (grade 1/2), median follow-up of 7.2 months. #cartsm #asco22 #asco22_szu #mediq22asco #eha2022
Chief of Myeloma @MSKCancerCenter | Chair @ALLIANCE_org #mmsm Comm. |Physician ? Provider| @ASH_hematology @ASTCT @ASCO |married to @ZainabShd | #BMTsm #CARTsm